Media Kit

Approved Company Description

Atomwise is a preclinical pharma company revolutionizing how drugs are discovered with AI. We invented the use of deep learning for structure-based drug discovery, today developing a pipeline of small-molecule drug candidates advancing into preclinical studies. Our AtomNet® technology has been used to unlock more undruggable targets than any other AI drug discovery platform. We are tackling over 600 unique disease targets with more than 250 partners around the world, including leading pharmaceutical, agrochemical, and emerging biotechnology companies. Atomwise has raised over $174 million from leading venture capital firms to advance our mission to make better medicines, faster.

Learn more at atomwise.com, or connect on Twitter and LinkedIn.

DOWNLOAD AS TEXT (.txt)

Meet Our CEO

Abraham Heifets, PhD
CEO, Founder

Abraham Heifets is the CEO of Atomwise, which uses artificial intelligence to help discover new medicine. Abraham was a Massey Fellow at the University of Toronto and the Ontario Brain Institute, where his doctoral work used machine learning to help plan organic syntheses, a long-standing challenge in chemistry. Previously, Abraham researched high-performance data processing at IBM's T.J. Watson Research Center and contributed to the artificial intelligence system of the world-champion robotic soccer team at Cornell University, from which he holds two previous degrees. Abraham has presented his work at the National Institutes of Health, the American Chemical Society, and the Association for the Advancement of Artificial Intelligence. He is an author on 19 papers, patents, and patent applications. Abraham was also named Time Magazine's Person of the Year in 2006.